Key Takeaways
- Health Canada is warning against the use of fake or unauthorized versions of GLP-1 drugs, such as semaglutide, due to serious health risks.
- Unauthorized or counterfeit drugs can contain incorrect or unknown ingredients, contaminants, or be poorly labeled, leading to serious health consequences.
- Health Canada has identified retailers selling unauthorized GLP-1 products in Canada, both in stores and online, and is working to stop these sales.
- The regulator advises people to only buy prescription drugs from licensed pharmacies and to check for the eight-digit Drug Identification Number (DIN) on the label to ensure the product is authorized.
- Health Canada is actively monitoring the marketplace and working with the Canada Border Services Agency to stop unauthorized shipments from entering the country.
Introduction to the Warning
Health Canada has issued a public advisory warning people not to buy or use fake or unauthorized versions of GLP-1 drugs, such as semaglutide, the active ingredient in Ozempic and Wegovy. The warning comes as interest grows in GLP-1 products for weight loss, and some people may turn to unauthorized or counterfeit products, which could pose serious health risks. The versions of the medications authorized for use in Canada are semaglutide (Ozempic and Wegovy injections and Rybelsus oral tablets) and tirzepatide (Mounjaro and Zepbound injections).
Risks Associated with Unauthorized Products
Unauthorized or counterfeit drugs carry many risks, including containing too much, too little, or none of the active ingredient, containing unlisted, dangerous or unknown ingredients, and containing contaminants such as solvents, heavy metals, particles, or microbials. Additionally, unauthorized or counterfeit injectable products carry even more risks, such as infections due to lack of sterility, allergic reactions, and other serious negative outcomes due to contamination, improper handling, or unsafe administration. Health Canada has identified various retailers in Canada selling unauthorized GLP-1 products, both in stores and online, and some websites and social media advertisements misuse official Health Canada logos and display fake endorsements to mislead consumers.
Regulatory Action
Selling unauthorized or counterfeit products or making false or misleading claims to prevent, treat, or cure illnesses is illegal in Canada. Health Canada has listed known risks associated with the use of genuine GLP-1 products, including severe gastrointestinal problems, pancreatitis, worsening kidney injury, and low blood sugar, particularly if combined with other medications. The regulator advises people to only buy prescription drugs from licensed pharmacies, do not buy or use unauthorized products, and look for drugs that have been authorized by Health Canada by checking for the eight-digit Drug Identification Number (DIN) on the label and by searching Health Canada’s drug product database.
Prevention and Safety Measures
To ensure safety, Health Canada advises people to speak with their healthcare professional if they have used an unauthorized GLP-1 product and have concerns about their health. Additionally, people should know the risks of buying drugs over the internet and know how to choose a safe online pharmacy. Health Canada also encourages people to report any health product-related side effects or complaints, including suspected counterfeit and unauthorized products, to the regulator. The regulator is actively monitoring the marketplace and can act by seizing products, and sending compliance or warning letters against the sale and advertisement of these products in stores and online.
International Cooperation
Health Canada is working closely with the Canada Border Services Agency (CBSA) to stop unauthorized shipments from entering the country. This cooperation is particularly important given the global nature of the problem. In June 2024, the World Health Organization warned of falsified semaglutides detected in Brazil, the United Kingdom, and the U.S. the previous year. This highlights the need for international cooperation to prevent the spread of unauthorized and counterfeit products. By working together, regulatory agencies can help protect public health and prevent the harm caused by these products.
Conclusion
In conclusion, Health Canada’s warning against the use of fake or unauthorized versions of GLP-1 drugs is an important reminder of the risks associated with these products. By being aware of the risks and taking steps to ensure safety, people can protect their health and well-being. It is essential to only buy prescription drugs from licensed pharmacies and to check for the eight-digit Drug Identification Number (DIN) on the label to ensure the product is authorized. Health Canada’s efforts to monitor the marketplace and stop unauthorized shipments are crucial in preventing the harm caused by these products, and international cooperation is necessary to address this global problem.